Please select the option that best describes you:
In patients with newly diagnosed HER2+ early breast cancer, what do you anticipate will become the standard sequencing for T-DXd, neoadjuvant (DB11) or adjuvant (DB05) treatment?
Or would you wait for other information/data before incorporating T-DXd in perioperative treatments? Harbeck et al., PMID 41130363